New Bone Regeneration Discovery Offers Hope for Osteoporosis Treatment

Trabecular Bone Renews Through Newly Identified Tunnels

Utilizing the Canadian Light Source to examine a rabbit’s Trabecular bone discovered that trabecular bone—which makes up roughly 20% of the adult skeleton and is found at the ends of long bones like the thigh bone and in the center of flat and irregular bones like vertebrae of the spine—renews itself through a previously unknown mechanism. According to researchers, what was once assumed to be evidence of bone loss caused by chronic kidney disease or disorders related to parathyroid hormone is actually a regenerative process.

Lisbeth Thomsen, a postdoctoral at USask, stated that when viewing the bones in real time, they seemed to be regenerating from the inside. Thomsen noted that researchers plan to measure how much it effects the strength of the bone and also try to learn more about what controls how these tunnels are forming, which is vital for understanding osteoporosis.

GPR133 Receptor Targeted to Reverse Bone Loss

In a separate study, scientists at Leipzig University have identified a little-studied receptor called GPR133 that appears to play a central role in maintaining bone strength by balancing the activity of key bone cells, according to lead investigator Professor Ines Liebscher. The receptor is switched on by mechanical strain and by contact between neighboring bone cells. Once activated, it promotes osteoblasts, which are cells responsible for building bone, while holding back osteoclasts, the cells that remove bone tissue.

According to the Leipzig team, if this receptor is impaired by genetic changes, mice show signs of loss of bone density at early age – similar to osteoporosis in humans. When researchers used the substance AP503, which was only recently identified via a computer-assisted screen as a stimulator of GPR133, they were able to significantly increase bone strength in both healthy and osteoporotic mice, including models designed to mimic postmenopausal bone loss.

Parallel Strengthening of Bone and Muscle

The research into AP503 also revealed potential applications beyond the skeletal system. In earlier work, the Leipzig team found that AP503 also strengthened skeletal muscle. Commenting on these results, Dr Juliane Lehmann, lead author of the study and a researcher at the Rudolf Schönheimer Institute of Biochemistry, stated that this parallel strengthening of bone once again highlights the great potential this receptor holds for medical applications in an ageing population where bone loss and muscle loss often happen together.

Because the current insights rely strictly on animal testing, investigators warn that further studies must take place prior to any human therapies becoming available.

Frequently Asked Questions

What causes osteoporosis?

Osteoporosis develops when that balance shifts in the wrong direction, leading to a net loss of bone density and increased fracture risk.

What is the GPR133 receptor?

Although part of a largely uncharted subclass of receptors, GPR133 shares a broader family with numerous therapeutics currently in widespread clinical use. According to Leipzig University researchers, activating this receptor supports bone formation while holding back bone breakdown.

Can these discoveries cure osteoporosis currently?

Not yet. Investigators point out that since current evidence is derived exclusively from animal models, additional research is required before any potential treatments can be tested in humans.